Comparison · NCT00718419-sae
Multiple Myeloma (MM) vs Waldenstrom's Macroglobulinemia (WM): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Multiple Myeloma (MM) vs Waldenstrom's Macroglobulinemia (WM): serious adverse events. Trial comparisons, record NCT00718419-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00718419-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.286 | 0.117 | 0.546 | wilson | |
| Risk in group 2 | 0.214 | 0.117 | 0.359 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0714 | -0.151 | 0.35 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.33 | 0.485 | 3.66 | log | |
| Odds ratio, group 1 over group 2 | 1.47 | 0.371 | 5.79 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Multiple Myeloma (MM) than on Waldenstrom's Macroglobulinemia (WM) | 14 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Multiple Myeloma (MM) | Participants diagnosed with MM received: Three 125-milligrams (mg) Enzastaurin tablets three times on Day 1 of Cycle 1 (Day 1 total dose = 1125 mg). Day 2 onwards and subsequent Cycles: Two 125-mg tablets orally twice a day (500 mg total per day). Cycle length (all cycles): 28 days. | 4 | 14 | EG000 |
| Group 2 | Waldenstrom's Macroglobulinemia (WM) | Participants diagnosed with WM received: Three 125-milligrams (mg) Enzastaurin tablets three times on Day 1 of Cycle 1 (Day 1 total dose = 1125 mg). Day 2 onwards and subsequent Cycles: Two 125-mg tablets orally twice a day (500 mg total per day). Cycle length (all cycles): 28 days. | 9 | 42 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma
- NCT number
- NCT00718419
- Phases
- PHASE2
- Conditions
- Waldenstrom's Macroglobulinemia, Multiple Myeloma
- Interventions
- Enzastaurin
- Lead sponsor
- Eli Lilly and Company
- Results first posted
- 2020-09-03
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00718419?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00718419-sae